Traws Pharma, Inc. announced on June 12, 2026, that the planned Phase 2a human influenza challenge study for tivoxavir marboxil has been deferred due to a negative review from the United Kingdom's Medicines and Healthcareproducts Regulatory Agency. Traws Pharma, Inc. is a pharmaceutical company focused on developing influenza treatments.
